The administration of Tocilizumab (antibody against IL-6:IL-6R) or Siltuximab (antibody against IL-6) at standard doses with or without dexamethasone rendered APVO436-associated severe CRS manageable and rapidly transient consistent with our current understanding of the IL-6 receptor signaling [59] and the standard management of this class-specific complication [27,28,29]. The gene discussed is IL6; the disease is congenital rubella syndrome.